Verastem Oncology (VSTM) 2012年年度报告「NASDAQ」.pdf

《Verastem Oncology (VSTM) 2012年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Verastem Oncology (VSTM) 2012年年度报告「NASDAQ」.pdf（149页珍藏版）》请在三个皮匠报告上搜索。

1、Use these links to rapidly review the documentTable of Contents Consolidated Financial Statements ContentsTable of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-KCommission file number 001-35403Verastem,Inc.(Exact name of registrant as specified in its charter)De

2、laware(State or other jurisdiction ofincorporation or organization)27-3269467(I.R.S.EmployerIdentification No.)215 First Street,Suite 440Cambridge,Massachusetts(Address of principal executiveoffices)02142(Zip Code)Registrants telephone number,including area code:(617)252-9300 Securities registered p

3、ursuant to Section 12(b)of the Act:Title of each class Name of each exchange on whichregisteredCommon Stock,$0.0001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rul

4、e 405 of the Securities Act.o Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.o Yes No(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2

5、012oro TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding

6、12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to suchfiling requirements for the past 90 days.Yes o No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website,if any,every Inte